Concord Healthcare Group Partners with Uzbekistan's Ministry of Health for Gamma Knife Centre

Stock News
07/29

CONCORD HC GP (02453) has announced a strategic collaboration with the Ministry of Health of the Republic of Uzbekistan.

Under the agreement, the group will construct and operate a Gamma Knife Radiosurgery Centre at the Tashkent National Medical Centre. This project is structured as a public-private partnership (PPP), leveraging the Ministry's local medical facilities, healthcare insurance systems, and regional resources. The company will fully fund and operate the centre over a 15-year period, sharing project revenue.

The initiative aims to strengthen advanced oncology radiotherapy services in Central Asia. It will also create synergies with the company's Guangzhou Concord Cancer Hospital (Guangzhou Hospital). This marks a key milestone in the company's international expansion into the Central Asian market.

By utilizing its mature expertise in oncology radiotherapy, Gamma Knife operations, and AI technology, the company is pursuing a capital-light, technology-driven export model. This project is designed as a replicable blueprint for overseas medical partnerships.

Once operational, the Gamma Knife business will complement the proton therapy services at Guangzhou Hospital. The partnership will establish a cross-border multidisciplinary consultation and patient referral system, enhancing brand influence. Furthermore, it will generate a new and stable source of overseas revenue, optimizing the company's income geography and enriching its high-end oncology radiotherapy service chain.

Building on this initial success, both parties plan to deepen their cooperation. Future areas of collaboration will include the joint construction and operation of additional radiotherapy centres, imaging diagnostic centres, and the application of artificial intelligence.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10